Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

A Zanichelli

Showing results (21-30 of 32) with videos related to

Pageof 4
Sort By:
European Annals of Allergy and Clinical Immunology|June 26, 2026
Clinical experience with berotralstat in patients with hereditary angioedema: an Italian case series from the ITACA cohortA Zanichelli, F Arcoleo, V Montinaro, et al.
Blood Cells, Molecules & Diseases|December 3, 2011
ABCB1 haplotype is associated with major molecular response in chronic myeloid leukemia patients treated with standard-dose of imatinibDouglas Vivona, Carolina T Bueno, Luciene T Lima, et al.
Clinical and Experimental Allergy : Journal of the British Society for Allergy and Clinical Immunology|August 23, 2012
Efficacy and safety of recombinant human C1-inhibitor for the treatment of attacks of hereditary angioedema: European open-label extension studyD Moldovan, A Reshef, J Fabiani, et al.
Allergy|March 29, 2014
Classification, diagnosis, and approach to treatment for angioedema: consensus report from the Hereditary Angioedema International Working GroupM Cicardi, W Aberer, A Banerji, et al.
Allergy|October 12, 2013
Repeat treatment with icatibant for multiple hereditary angioedema attacks: FAST-2 open-label studyM Baş, J Greve, T K Hoffmann, et al.
Cell Death & Disease|October 13, 2017
BCR-ABL1-induced downregulation of WASP in chronic myeloid leukemia involves epigenetic modification and contributes to malignancyWelbert O Pereira, Daniel D De Carvalho, Maria Emilia Zenteno, et al.
Oncogene|September 15, 2010
BCR-ABL-mediated upregulation of PRAME is responsible for knocking down TRAIL in CML patientsD D De Carvalho, R Binato, W O Pereira, et al.
Medical Oncology (Northwood, London, England)|January 29, 2014
Reduced ABCG2 and increased SLC22A1 mRNA expression are associated with imatinib response in chronic myeloid leukemiaLuciene Terezina de Lima, Douglas Vivona, Carolina Tosin Bueno, et al.
Frontiers in Immunology|November 4, 2024
Rare connective tissue diseases in patients with C1-inhibitor deficiency hereditary angioedema: first evidence on prevalence and distribution from a large Italian cohort studyP Triggianese, R Senter, F Perego, et al.
Bone Marrow Transplantation|April 18, 2007
Epidemiology of bacteremia and factors associated with multi-drug-resistant gram-negative bacteremia in hematopoietic stem cell transplant recipientsA L Oliveira, M de Souza, V M H Carvalho-Dias, et al.
Pageof 4

Showing results (21-30 of 32) with videos related to

Sort By:
Pageof 4
European Annals of Allergy and Clinical Immunology|June 26, 2026
Clinical experience with berotralstat in patients with hereditary angioedema: an Italian case series from the ITACA cohortA Zanichelli, F Arcoleo, V Montinaro, et al.
Blood Cells, Molecules & Diseases|December 3, 2011
ABCB1 haplotype is associated with major molecular response in chronic myeloid leukemia patients treated with standard-dose of imatinibDouglas Vivona, Carolina T Bueno, Luciene T Lima, et al.
Clinical and Experimental Allergy : Journal of the British Society for Allergy and Clinical Immunology|August 23, 2012
Efficacy and safety of recombinant human C1-inhibitor for the treatment of attacks of hereditary angioedema: European open-label extension studyD Moldovan, A Reshef, J Fabiani, et al.
Allergy|March 29, 2014
Classification, diagnosis, and approach to treatment for angioedema: consensus report from the Hereditary Angioedema International Working GroupM Cicardi, W Aberer, A Banerji, et al.
Allergy|October 12, 2013
Repeat treatment with icatibant for multiple hereditary angioedema attacks: FAST-2 open-label studyM Baş, J Greve, T K Hoffmann, et al.
Cell Death & Disease|October 13, 2017
BCR-ABL1-induced downregulation of WASP in chronic myeloid leukemia involves epigenetic modification and contributes to malignancyWelbert O Pereira, Daniel D De Carvalho, Maria Emilia Zenteno, et al.
Oncogene|September 15, 2010
BCR-ABL-mediated upregulation of PRAME is responsible for knocking down TRAIL in CML patientsD D De Carvalho, R Binato, W O Pereira, et al.
Medical Oncology (Northwood, London, England)|January 29, 2014
Reduced ABCG2 and increased SLC22A1 mRNA expression are associated with imatinib response in chronic myeloid leukemiaLuciene Terezina de Lima, Douglas Vivona, Carolina Tosin Bueno, et al.
Frontiers in Immunology|November 4, 2024
Rare connective tissue diseases in patients with C1-inhibitor deficiency hereditary angioedema: first evidence on prevalence and distribution from a large Italian cohort studyP Triggianese, R Senter, F Perego, et al.
Bone Marrow Transplantation|April 18, 2007
Epidemiology of bacteremia and factors associated with multi-drug-resistant gram-negative bacteremia in hematopoietic stem cell transplant recipientsA L Oliveira, M de Souza, V M H Carvalho-Dias, et al.
Pageof 4